ClinicalTrials.Veeva

Menu

PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Mastectomy (PRECISE)

Medtronic logo

Medtronic

Status

Terminated

Conditions

Mastectomy

Treatments

Device: Scalpel and Traditional Electrosurgery
Device: PEAK PlasmaBlade

Study type

Interventional

Funder types

Industry

Identifiers

NCT00943605
PEAK VP-00074

Details and patient eligibility

About

The objective of this clinical study is to evaluate the incidence of partial skin necrosis following modified-radical mastectomy with or without same-day (two-stage) reconstruction with the PEAK PlasmaBlade 4.0; to monitor and record operative performance, post-operative pain, drain output, and skin scarring following surgery; and to compare these endpoints to the current standard of care (SOC).

Full description

Mastectomy is a surgical procedure performed to remove breast tissue that contains cancer, or has a high probability of containing cancer. During the procedure, a scalpel is used for the skin incision and a traditional electrosurgical device is used to cut away the breast tissue from the chest and control bleeding. Once the breast tissue is removed the remaining skin edges are brought together with sutures.

Following mastectomy, the most common complication is persistent serous wound drainage and seroma, a collection of fluid in the closed surgical space. To help prevent this complication a tissue drain is used to remove serous fluid from the surgical space via bulb suction. The rate of serous fluid collection is used to determine the time the drain remains in place. Although suction drains help reduce seroma formation, prolonged use may delay healing, cause injury, and increase the risk of infection and patient discomfort.

The PEAK PlasmaBlade™ uses pulsed radiofrequency (RF) energy to enable precision cutting and coagulating at the point of application, without the thermal damage to surrounding tissues that is normally seen with traditional electrosurgery. The PlasmaBlade has received FDA clearance for use in plastic, general, and ENT surgery, and has demonstrated significantly reduced serous drainage in tissue reduction surgeries, like mastectomy.

This multi-site study was granted IRB approval and conducted between June 2009 and January 2011. Potential subjects were screened against the inclusion and exclusion criteria of the study protocol and were then required to provide informed consent prior to enrollment. Following enrollment, subjects were prospectively randomized to the SOC or PlasmaBlade (PB or PEAK) study groups and scheduled for mastectomy with or without same day reconstruction.

Enrollment

60 patients

Sex

Female

Ages

20 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age between 20 and 70 years old
  2. Physically healthy, stable weight
  3. Requiring single or bilateral simple mastectomy, with or without sentinel lymph node biopsy
  4. Subject must understand the nature of the procedure and provide written informed consent prior to the procedure
  5. Subject must be willing and able to comply with all follow-up evaluations

Exclusion criteria

  1. Age younger than 20 or greater than 70 years old
  2. Anticoagulation therapy which cannot be discontinued
  3. Prior external beam or implanted radiotherapy
  4. Tobacco use (any kind)
  5. Infection (local or systemic)
  6. Cognitive impairment or mental illness
  7. Severe cardiopulmonary deficiencies
  8. Known coagulopathy
  9. Immunocompromised
  10. Kidney disease (any type)
  11. Desiring or requiring same-day breast reconstruction
  12. Prior breast reduction or augmentation surgery
  13. Unable to follow instructions or complete follow-up
  14. Currently taking any medication known to affect healing
  15. Subjects who are status-post gastric banding or gastric bypass
  16. Currently enrolled in another investigational device or drug trial
  17. Time from most recent neoadjuvant therapy less than 4 weeks

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

60 participants in 2 patient groups

Standard of Care
Active Comparator group
Description:
Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
Treatment:
Device: Scalpel and Traditional Electrosurgery
PEAK PlasmaBlade
Experimental group
Description:
The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
Treatment:
Device: PEAK PlasmaBlade

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems